Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

istry and RNAi delivery. The Company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties regarding regulatory approvals for future clinical testing of arimoclomol, including CytRx's planned Phase IIb clinical trial, and the scope of the clinical testing that may be required by regulatory authorities for arimoclomol, risks related to any comparison of clinical data to historical controls in the absence of concurrent placebo controls, uncertainties regarding the timing and amount of revenues, if any, that will be realized by CytRx from the commercialization of arimoclomol, the significant time and expense that will be incurred in developing any of the potential commercial applications for arimoclomol and the potential need for additional capital to fund the development of arimoclomol, as well as other risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon informat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:9/20/2014)... 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, in ... its Mylan-Nitro Spray 0.4 mg/metered dose due to the product ... component. A missing "dip tube" could pose ... patient. This defect may lead patients to believe they are ... access it. Not receiving nitroglycerin could place them at risk ...
(Date:9/19/2014)... , Sept. 19, 2014 Medical ... forging relationships with key opinion leaders (KOLs) who ... competition. Despite the critical nature of the MSL ... challenges, including altering the landscape for creating and ... According to research, the oversight responsibility for the ...
(Date:9/19/2014)... 19, 2014 Harwood Feffer LLP ( www.hfesq.com ... directors of PDL BioPharma, Inc. ("PDL" or the "Company") ... has breached its fiduciary duties to shareholders or violated ... 2014, the Company disclosed: "On September 11, 2014, [PDL] ... Ernst & Young LLP ("EY"), that it was resigning ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... a,division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today,that the ... pediatric,exclusivity for TOPAMAX(R) (topiramate), based on studies submitted ... to investigate the use of TOPAMAX,in pediatric patients ... seizures., In addition to granting pediatric exclusivity, ...
... There are a record 301,new medicines being ... released here today during a briefing that focused ... patients, their families,and society. Nationwide, mental illness affects ... the Pharmaceutical Research and Manufacturers,of America (PhRMA), featured ...
Cached Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4
(Date:9/20/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer ... party dresses . In addition, the company has launched a ... the promotion is to benefit all of its big fans. ... store now. , Along with beautiful party dresses, the ... has recently released its new sexy short prom outfits and ...
(Date:9/20/2014)... (PRWEB) September 21, 2014 Recently, UWDress.com, ... has launched a promotion for its newly announced ... most of the company’s special occasion outfits are very ... outfits are provided with big savings (up to 65 ... hard to offer more fashionable special occasion outfits for ...
(Date:9/20/2014)... NV (PRWEB) September 21, 2014 ... Dr. Kenneth Pullman that is helping thousands of people ... diabetes symptoms without shots, pills, or prescriptions has caught ... , “There are currently tens of millions of ... Type 1 and Type 2 diabetes, and unfortunately, big ...
(Date:9/20/2014)... 21, 2014 Weight Destroyer , ... fitness expert Michael Wren that has already helped tens ... reverse health conditions like high blood pressure, high cholesterol, ... Michaels, prompting an investigative review. , “Weight Destroyer ... upside down by showing people what is truly effective ...
(Date:9/20/2014)... 6 Minutes to Skinny , a ... Ballantyne that is showing men and women of all ages ... body fat using simple 6-minute exercises and easy-to-follow lifestyle tips ... investigative review. , “When it comes to losing body ... out for all people,” reports Michaels. “Metabolism plays a big ...
Breaking Medicine News(10 mins):Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:6 Minutes to Skinny: Review Exposes Craig Ballantyne’s Method to Jump Starting the Metabolism and Blasting Away Body Fat in Just 6 Minutes Per Day 2
... cancer is expected to be unsuccessful. Statisticians with the US ... in the hunt for common inherited genetic variants that would ... there are a number of problems when doing such a ... that common genes are unlikely to exist nor have ...
... With one of the highest percentages of undernourished children ... states a new World Bank report released Thursday//. ... significant changes to address the current malnutrition crisis," states ... and Action". ,The prevalence of underweight children in ...
... Cancer Institute in Bethesda, Maryland, and Jaakko Kaprio, a genetic ... waste of time and money to search for genes linked ... Medical Journal. They say that there is very little chance ... is being invested. Researchers believe that if they can identify ...
... should practice less invasive surgery for by pass surgery. They ... increase the chances of exposing patients to innumerable infections. Most ... infections. In the traditional method the great saphenous vein is ... This enhances the blood flow to the heart muscle ...
... of the American Society of Nephrology has stated that ... failure//. ,"Our results confirm an accumulating body of ... causative factor in kidney disease," comments Dr. Elisabeth Ejerblad ... study. ,Dr. Ejerblad and colleagues assessed body mass ...
... will help cigarette smokers to quit smoking, wins ... active ingredient in Chantix is varenicline tartrate. The ... better effectiveness shown in preliminary trials compared to ... priority review get approved or rejected within six ...
Cached Medicine News:Health News:Malnutrition Crisis On Rise In India: World Bank 2Health News:Kidney Failure three times pronounced with obesity 2
An entirely new way to brighten and enhance natural eye color....
Disposable-type color lenses for exciting eye color change....
... The world standard in corneal ... like endothelium, descemet's membrane, stroma, Bowman's ... of Corneal Components. Broad Applications in ... pachymetry, post-surgery interface evaluation, endothelial cell ...
... Vasculight SR improves the appearance of photo-aged ... benign brown pigments, telangiectasias, and broken capillaries. ... pulsed light (IPLTM) treats pigmentary sun damage ... combined approach of IPL and the Nd:YAG ...
Medicine Products: